Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) -Intergroup Study of NOGGO und Studiengruppe.
NEW AGENTS ON THE HORIZON: IMPLICATIONS FOR PHASE I, II & III TRIALS DNA Repair and PARP inhibitors Carol Aghajanian, Nicoletta Colombo & Amit Oza Acknowledgements: